Stay updated with breaking news from Raajitk rampal. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Updated MANIFEST-2 Data With Pelabresib/Ruxolitinib Support Paradigm Shift in Myelofibrosis onclive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from onclive.com Daily Mail and Mail on Sunday newspapers.
Andrew Kuykendall, MD, and Raajit K. Rampal, MD, PhD, conclude that the increasing complexity in myelofibrosis treatment options, including multiple JAK inhibitors and emerging combination therapies, signals an exciting era of individualized care, yet underscores the need for reevaluating study end points to enhance patient outcomes further. ....
Raajit K. Rampal, MD, PhD, discusses choosing among JAK inhibitors based on specific patient needs, such as platelet counts and anemia, emphasizing the importance of using the full dose for best efficacy and how different scenarios might influence the choice and sequencing of these drugs in practice. ....
Andrew Kuykendall, MD, and Raajit K. Rampal, MD, PhD, reflect on the future of combination therapies in treating myelofibrosis, emphasizing the need to align study endpoints with treatment goals and highlighting the potential of various combinations based on promising preclinical and early phase study results. ....
Adding pelabresib to treatment with ruxolitinib reduced spleen size in patients with JAK inhibitor-naïve myelofibrosis in the phase 3 MANIFEST-2 trial. Adding pelabresib to treatment with ruxolitinib reduced spleen size in patients with JAK inhibitor-naïve myelofibrosis in the phase 3 MANIFEST-2 trial. ....